+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028

  • ID: 5450247
  • Report
  • September 2021
  • Region: Global
  • 110 Pages
  • Grand View Research

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cambrex
  • Catalent
  • Corden Pharma
  • Lonza
  • Pantheon
The global antibody drug conjugates contract manufacturing market size is anticipated to reach USD 18.4billion by 2028, according to a new report by the publisher The market is expected to expand at a CAGR of 12.3% from 2021 to 2028. The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies.



Around 70.0% of ADC projects are outsourced to contract development and manufacturing organisations. As ADCs are complex molecules, they require clean room biologic and high containment cytotoxic facilities for safe handling. Hence, there are real opportunities for companies that can provide specialised, innovative chemistries that require skilled workers.

ADCs are currently a niche market, with few CMOs offering all of the drug's components, resulting in a complex supply chain. Besides, with seven commercially authorised ADC on the market and roughly 90 projects in clinical trials, it is essential to reduce the complicated supply chain in order to increase production efficiency. For the success of the trial, a transparent and integrated supply chain is essential.

The coronavirus pandemic has assessed a typically optimistic and deliberate approach to monoclonal antibody development and disrupting supply chains not only for those antibodies deemed most promising a year ago, but also for others antibody drug conjugate that have been thrust into the spotlight as potential COVID-19 treatments.The COVID-19 pandemic has generated a strong and quick reaction from scientists working in government, and industries to create medicines and vaccines. As a result of the increasing demand for effective COVID-19 treatment medicines, global production of vaccines, antibody drug conjugates, and other pharmaceuticals is projected to expand.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

  • By condition, the myeloma segment dominated the market and accounted for the largest revenue share of 49.4% in 2020. This is largely due to the fact that antibody-drug conjugates are a novel form of immunotherapy presently being researched and evaluated in the treatment of myeloma
  • Based on the linker, the cleavable linker segment accounted for a maximum share of 56.5% in 2020. Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based authorised products are the factor responsible for the growth
  • Asia Pacific dominated themarket in 2020 due to the robust improvements in research and development activities, emerging markets, and competition in the pharmaceutical CMO sector
  • In 2018, nearly 202 ADCs have entered the clinical trials and there were about 23 novel ADCs in the last 12 months increasing at a rate of 30.0%


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Antibody Drug Conjugates Contract Manufacturing Market

What is the estimated value of the Antibody Drug Conjugates Contract Manufacturing Market?

The Antibody Drug Conjugates Contract Manufacturing Market was estimated to be valued at $7.2 Billion in 2020.

What is the growth rate of the Antibody Drug Conjugates Contract Manufacturing Market?

The growth rate of the Antibody Drug Conjugates Contract Manufacturing Market is 12.3%, with an estimated value of $18.4 Billion by 2028.

What is the forecasted size of the Antibody Drug Conjugates Contract Manufacturing Market?

The Antibody Drug Conjugates Contract Manufacturing Market is estimated to be worth $18.4 Billion by 2028.

Who are the key companies in the Antibody Drug Conjugates Contract Manufacturing Market?

Key companies in the Antibody Drug Conjugates Contract Manufacturing Market include Cambrex, ReciPharm, ThermoFisher, Pantheon, Corden Pharma, Samsung Biologics, Lonza, Catalent and Piramal Pharma Solutions.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cambrex
  • Catalent
  • Corden Pharma
  • Lonza
  • Pantheon

Chapter 1 Report Scope
1.1 Segment Scope
1.2 Regional Scope
Chapter 2 Methodology
2.1 Research Methodology
2.1.1 Information Procurement
2.2 Information Or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Wise Market Calculation
2.4.1 Approaches Used To Estimate The Market Size
2.4.1.1 Approach 1: Region Wise Market Estimation Using Bottom-Up Approach
2.4.1.2 Approach 2: Parent Market Analysis
2.4.1.3 Approach 3: Commodity Flow
2.4.2 Global Market: Cagr Calculation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.6 List of Secondary Sources
2.7 List of Primary Sources
2.8 List of Abbreviations
Chapter 3 Objectives
3.1 Objective - 1: Understanding the market dynamics
3.2 Objective - 2: Understanding the market estimates and forecasts
3.3 Objective - 3: Understanding the attributes such as strategy framework, competitor categorization
3.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
Chapter 4 Executive Summary
4.1 Market Outlook
4.2 Segment Outlook
4.3 Competitive Insights
Chapter 5 Antibody drug conjugates contract manufacturing market: Variables, Trends & Scope
5.1 Market Lineage Outlook
5.1.1 Parent Market Outlook
5.1.2 Ancillary Market Outlook
5.2 Penetration & Growth Prospect Mapping
5.3 Market Variable Analysis
5.3.1 Market Driver Analysis
5.3.1.1 Rising Prevalence Of Cancer
5.3.1.2 Advancemtent In Medical Technology
5.3.1.3 Increasing Demand For The Biologic Therapy
5.3.2 Market Restraint Analysis
5.3.2.1 High Manufacturing Cost Of Antibody Drug Conjugates
5.4 Antibody Drug Conjugates Contract Manufacturing Market: Analysis Tools
5.4.1 Porter’s Five Forces Analysis
5.4.2 Pestel Analysis
5.4.3 Major Deals & Strategic Alliances Analysis
Chapter 6 Antibody drug conjugates contract manufacturing market: Condition Segment Analysis
6.1 Antibody drug conjugates contract manufacturing market : Definition & Scope
6.2 Antibody drug conjugates contract manufacturing market: Market Share Analysis, 2020 & 2028
6.3 Myeloma
6.3.1 Myeloma Market, 2016 - 2028 (USD Million)
6.3.2 Lymphoma
6.3.2.1 Lymphoma Market, 2016 - 2028 (USD Million)
6.3.3 Breast Cancer
6.3.3.1 Breast Cancer Market, 2016 - 2028 (USD Million)
6.3.4 Others (Urothelial Cancer)
6.3.4.1 Others (Urothelial Cancer) Market, 2016 - 2028 (USD Million)
Chapter 7 Antibody drug conjugates contract manufacturing market : Linker Segment Analysis
7.1 Antibody drug conjugates contract manufacturing market: Definition & Scope
7.2 Antibody drug conjugates contract manufacturing market: Market Share Analysis, 2020 & 2028
7.3 Cleavable Linker
7.3.1 Cleavable Linker Market, 2016 - 2028 (USD Million)
7.4 Non-cleavable Linker
7.4.1 Non-cleavable Linker Market, 2016 - 2028 (USD Million)
Chapter 8 Antibody drug conjugates contract manufacturing market: Regional Analysis
8.1 Antibody drug conjugates contract manufacturing market: Definition & Scope
8.2 Regional Market Snapshot
8.3 Antibody drug conjugates contract manufacturing market: Market Share Analysis, 2020 & 2028
8.4 North America
8.4.1 North America antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.4.2 U.S.
8.4.2.1 U.S. antibody drug conjugates contract manufacturing market , 2016 - 2028 (USD Million)
8.4.3 Canada
8.4.3.1 Canada antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.5 Europe
8.5.1 Europe antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.5.2 France
8.5.2.1 France antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.5.3 U.K.
8.5.3.1 U.K. antibody drug conjugates contract manufacturing market , 2016 - 2028 (USD Million)
8.5.4 Germany
8.5.4.1 Germany antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.5.5 Italy
8.5.5.1 Italy antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.5.6 Spain
8.5.6.1 Spain antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.6 Asia Pacific
8.6.1 Asia pacific antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.6.2 Japan
8.6.2.1 Japan antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.6.3 China
8.6.3.1 China stair lift and climbing devices market, 2016 - 2028 (USD Million)
8.6.4 India
8.6.4.1 India antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.6.5 South Korea
8.6.5.1 South korea antibody drug conjugates contract manufacturing market , 2016 - 2028 (USD Million)
8.6.6 Australia
8.6.61 Australia antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.7 Latin America
8.7.1 Latin america antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.7.2 Brazil
8.7.2.1 Brazil antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.7.3 Mexico
8.7.3.1 Mexico antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.7.4 Argentina
8.7.4.1 Argentina antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.8 MEA
8.8.1 MEA antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.8.2 South Africa
8.8.2.1 South Africa antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.8.3 Saudi Arabia
8.8.3.1 Saudi Arabia antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
8.8.4 UAE
8.8.4.1 UAE antibody drug conjugates contract manufacturing market, 2016 - 2028 (USD Million)
Chapter 9 Company Profiles
9.1 Cambrex
9.1.1 Company Overview
9.1.2 Financial Performance
9.1.3 Service Benchmarking
9.1.4 Strategic Initiatives
9.2 ReciPharm
9.2.1 Company Overview
9.2.2 Service Benchmarking
9.2.3 Strategic Initiatives
9.3 ThermoFisher
9.3.1 Company Overview
9.3.2 Financial Performance
9.3.3 Service Benchmarking
9.3.4 Strategic Initiatives
9.4 Pantheon
9.4.1 Company Overview
9.4.2 Financial Performance
9.4.3 Service Benchmarking
9.4.4 Strategic Initiatives
9.5 Corden Pharma
9.5.1 Company Overview
9.5.2 Financial Performance
9.5.3 Service Benchmarking
9.5.4 Strategic Initiatives
9.6 Samsung Biologics
9.6.1 Company Overview
9.6.2 Financial Performance
9.6.3 Service Benchmarking
9.6.4 Strategic Initiatives
9.7 Lonza
9.7.1 Company Overview
9.7.2 Financial Performance
9.7.3 Service Benchmarking
9.7.4 Strategic Initiatives
9.8 Catalent
9.8.1 Company Overview
9.8.2 Financial Performance
9.8.3 Service Benchmarking
9.9 Siegfried
9.9.1 Company Overview
9.9.2 Financial Performance
9.9.3 Service Benchmarking
9.9.4 Strategic Initiatives
9.10 Piramal Pharma Solutions
9.10.1 Company Overview
9.10.2 Service Benchmarking
9.10.3 Strategic Initiatives
9.11 Boehringer Ingelheim
9.11.1 Company Overview
9.11.2 Service Benchmarking
9.11.3 Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 List of Secondary Sources
Table 3 Global antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 4 Global antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 5 Global antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 6 North America Antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 7 North America Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 8 North America Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 9 U.S. Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 10 U.S. Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 11 Canada Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 12 Canada Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 13 Europe Antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 14 Europe Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 15 Europe Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 16 U.K. Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 17 U.K. Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 18 Germany Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 19 Germany Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 20 Spain Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 21 Spain Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 22 France Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 23 France Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 24 Italy Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 25 Italy Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 26 Asia Pacific Antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 27 Asia Pacific Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 28 Asia Pacific Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 29 China Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 30 China Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 31 India Antibody drug conjugates contract manufacturing market, by condition, (USD Million) 2016 - 2028 (USD Million)
Table 32 India Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 33 Japan Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 34 Japan Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 35 Australia Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 36 Australia Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 37 South Korea Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 38 South Korea Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 39 Latin America Antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 40 Latin America Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 41 Latin America Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 42 Brazil Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 43 Brazil Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 44 Mexico Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 45 Mexico Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 46 Argentina Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 47 Argentina Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 48 MEA Antibody drug conjugates contract manufacturing market, by region, 2016 - 2028 (USD Million)
Table 49 MEA Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 50 MEA Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 51 South Africa Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 52 South Africa Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 53 Saudi Arabia Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 54 Saudi Arabia Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
Table 55 UAE Antibody drug conjugates contract manufacturing market, by condition, 2016 - 2028 (USD Million)
Table 56 UAE Antibody drug conjugates contract manufacturing market, by linker, 2016 - 2028 (USD Million)
List of Figures
Figure. 1 Market research process
Figure. 2 Information procurement
Figure. 3 Primary research pattern
Figure. 4 Market research approaches
Figure. 5 QFD modeling for market share assessment
Figure. 6 Market formulation & validation
Figure. 7 Commodity Flow Analysis
Figure. 8 Antibody drug conjugates contract manufacturing market snapshot (2020)
Figure. 9 Antibody drug conjugates contract manufacturing market segmentation
Figure. 10 Antibody drug conjugates contract manufacturing market: Strategy framework
Figure. 11 Parent market outlook
Figure. 12 Related/ancillary market outlook
Figure. 13 Penetration & growth prospect mapping
Figure. 14 Market driver relevance analysis (Current & future impact)
Figure. 15 Market restraint relevance analysis (Current & future impact)
Figure. 16 Porter’s five forces analysis
Figure. 17 SWOT analysis, by factor (political & legal, economic and technological)
Figure. 18 Antibody drug conjugates contract manufacturing market: Component movement analysis
Figure. 19 Antibody drug conjugates contract manufacturing market condition outlook: Segment Dashboard
Figure. 20 Antibody drug conjugates contract manufacturing market: Condition movement analysis
Figure. 21 Myeloma market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 22 Lymphoma market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 23 Breast cancer market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 24 Others (urothelial cancer) market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 25 Antibody drug conjugates contract manufacturing market linker outlook: Segment Dashboard
Figure. 26 Antibody drug conjugates contract manufacturing market: Linker movement analysis
Figure. 27 Cleavable linker market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 28 Non-cleavable linker market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 29 Regional market place: Dashboard
Figure. 30 Antibody drug conjugates contract manufacturing market: Definition & Scope
Figure. 31 Regional Market Snapshot (Figures in USD Billion, 2018)
Figure. 32 Regional outlook, 2020 & 2028
Figure. 33 North America market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 34 U.S. market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 35 Canada market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 36 Europe market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 37 France market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 38 U.K. market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 39 Germany market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 40 Italy market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 41 Spain market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 42 Asia Pacific market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 43 Japan market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 44 China market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 45 India market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 46 South Korea market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 47 Australia market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 48 Latin America market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 49 Brazil market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 50 Mexico market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 51 Argentina market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 52 MEA market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 53 South Africa market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 54 Saudi Arabia market estimates and forecast, 2016 - 2028 (USD Million)
Figure. 55 UAE market estimates and forecast, 2016 - 2028 (USD Million)
Note: Product cover images may vary from those shown
  • Cambrex
  • ReciPharm
  • ThermoFisher
  • Pantheon
  • Corden Pharma
  • Samsung Biologics
  • Lonza
  • Catalent
  • Siegfried
  • Piramal Pharma Solutions
  • Boehringer Ingelheim
Note: Product cover images may vary from those shown

Loading
LOADING...